Abstract
The ROX CONTROL HTN study demonstrated the efficacy of arteriovenous coupler therapy in patients with resistant hypertension. However, one-third of the patients developed late ipsilateral venous stenosis, which required venoplasty or stenting. Future research is needed to identify the risk–benefit ratio of this new approach.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
